Melanoma-inhibitory activity protein concentrations in the blood of melanoma patients treated with immunotherapy

Oncology Research

Volumn 11, Issue 1, 1999, Pages 55-61

  Dreau D ^a   Bosserhoff, A K ^b   White, R L ^a   Buettner, R ^b   Holder, W D ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Blood; ELISA; IFN 2b; IL 2; Immunotherapy; Marker; Melanoma; Melanoma inhibitory activity protein (MIA); Threshold; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; INTERLEUKIN 2; MIA PROTEIN, HUMAN; SCLEROPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; DISEASE COURSE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0032602322     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Johnson, T. M.; Yahanda, A. M.; Chang, A. E.; Fader, D. J.; Sondak, V. K. Advances in melanoma therapy. J. Am. Acad. Dermatol. 38:731-741; 1998.
2. Rigel, D. S. Malignant melanoma: Incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin. Proc. 72:367-371; 1997.
3. American Cancer Society. Cancer facts & figures - 1998. Atlanta: American Cancer Society, Inc.; 1998.
4. Robinson, J. K.; Amonette, R.; Wyatt, S. W.; Bewerse, B. A.; Bergfeld, W. F.; Farris, P. K. Executive summary of the national "Sun Safety: Protecting Our Future." J. Am. Acad. Dermatol. 38: 774-780; 1998.
5. Robinson, J. K.; Rigel, D. S.; Amonette, R. A. What promote skin self-examination? J. Am. Acad. Dermatol. 39:752-757; 1998.
6. Runkle, G. P.; Zaloznik, A. J. Malignant melanoma. Am. Fam. Physician 49:91-98; 1994.
7. Raj, G. V.; Moreno, J. G.; Cornelia, L. G. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 82:1419-1442; 1998.
8. Weiss, M.; Loprinzi, C. L.; Creagan, E. T.; Dalton, R. J.; Novotny, P.; O'Fallon, J. R. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274:17031705; 1995.
9. Hoh, C. K.; Schiepers, C.; Seltzer, M. A.; Gambhir, S. S.; Silverman, D. H.; Czernin, J.; Maddahi, J.; Phelps, M. E. PET in oncology: Will it replace the other modalities? Semin. Nucl. Med. 27: 94-106; 1997.
10. Catalona, W. J.; Partin, A. W.; Slawin, K. M.; Brawer, M. K.; Flanigan, R. C.; Patel, A.; Richie, J. P.; deKernion, J. B.; Walsh, P. C.; Scardino, P. T.; Lange, P. H.; Subong, E. N.; Parson, R. E.; Gasior, G. H.; Loveland, K. G.; Southwick, P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279:1542-1547; 1998.
11. Cochran, A. J.; Lu, H. F.; Li, P. X.; Saxton, R.; Wen, D. R. S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res. 3:325-330; 1993.
12. Blessing, K.; Sanders, D. S.; Grant, J. J. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32:139-146; 1998.
13. Bosserhoff, A. K.; Kaufmann, M.; Kaluza, B.; Banke, I.; Zirngibl, H.; Hein, R.; Stolz, W.; Buettner, R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57:3149-3153; 1997.
14. Miliotes, G.; Lyman, G. H.; Cruse, C. W.; Puleo, C.; Albertini, P. A.; Rapaport, D.; Fenske, N.; Soriano, T.; Cuny, C.; Van Voorhis, N.; Reinigen, D. Evaluation of new putative tumor markers for melanoma. Ann. Surg. Oncol. 3:558-563; 1996.
15. Glaser, R.; Rass, K.; Seiter, S.; Hauschild, A.; Christophers, E.; Tilgen, W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J. Clin. Oncol. 15:2818-2825; 1997.
16. Reinhold, U.; Ludtkehandjery, H. C.; Schnautz, S.; Kreysel, H. W.; Abken, H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J. Invest. Dermatol. 108:166-169; 1997.
17. Sarantou, T.; Chi, D. D.; Garrison, D. A.; Conrad, A. J.; Schmid, P.; Morton, D. L.; Hoon, D. S. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 57: 1371-1376; 1997.
18. Reintgen, D. S.; Cruse, C. W.; Wells, K. E.; Saba, H. I.; Fabri, P. J. The evaluation of putative tumor markers for malignant melanoma. Ann. Plast. Surg. 28:55-59; 1992.
19. Bogdahn, U.; Apfel, R.; Hahn, M.; Gerlach, M.; Behl, C.; Hoppe, J.; Martin, R. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 49:5358-5363; 1989.
20. Apfel, R.; Lottspeich, F.; Hoppe, J.; Behl, C.; Dürr, G.; Bogdahn, U. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res. 2:327-336; 1992.
21. Bosserhoff, A. K.; Hein, R.; Wach, F.; Buettner, R. Function of MIA in metastatis of malignant melanoma. Proc. Am. Assoc. Cancer Res. 38:290; 1997.
22. Bosserhoff, A. K.; Kondo, S.; Moser, M.; Dietz, U. H.; Copeland, N. G.; Gilbert, D. J.; Jenkins, N. A.; Buettner, R.; Sandell, L. J. Mouse CD-RAP/MIA gene: Structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev. Dyn. 208: 516-525; 1997.
23. Martini, L.; Brandani, P.; Chiarugi, C.; Reali, U. M. First recurrence analysis of 840 cutaneous melanomas: A proposal for a follow-up schedule. Tumori 80:188-197; 1994.
24. Soong, S. J.; Harrison, R. A.; McCarthy, W. H.; Urist, M. M.; Balch, C. M. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J. Surg. Oncol. 67:228-233; 1998.
25. Morton, D. L.; Foshag, L. J.; Hoon, D. S.; Nizze, J. A.; Famatiga, E.; Wanek, L. A.; Chang, C.; Davtyan, D. G.; Gupta, R. K.; Elashoff. R.; Irie, R. F. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216:463-482; 1992.
26. Morton, D. L.; Earth, A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin. 46:225-244; 1996.
27. Dréau, D.; Foster, M.; Culberson, C.; Holder, W. D. J. Specific IgG immune responses in melanoma patients treated with cell-vaccine. Proc. Am. Assoc. Cancer Res. 38:396; 1997.
28. Dréau, D.; Foster, M.; Culberson, C.; Hogg, M.; Pitman, P.; Holder, W. D. Cellular immune responses in melanoma patients following cell-vaccine immunotherapy. Proc. Am. Assoc. Cancer Res. 39:357; 1998.
29. Kirkwood, J. M.; Strawderman, M. H.; Ernstoff, M. S.; Smith, T. J.; Borden, E. C.; Blum, R. H. IFN-α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14:7-17; 1996.
30. Sackett, D. L.; Haynes, R. B.; Guyatt, G. H.; Tugwell, P. The interpretation of diagnostic data. In: Sackett, D. L.; Hyanes, R. B.; Guyatt, G. H.; Tugwell, P., eds. Clinical epidemiology. A basic science for clinical medicine. Boston: Little, Brown and Company; 1991:69-152.
31. Fusi, S.; Ariyan, S.; Sternlicht, A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast. Reconst. Surg. 91:94-98; 1993.
32. Rossi, C. R.; Foletto, M.; Vecchiato, A.; Alessio, S.; Menin, N.; Lise, M. Management of cutaneous melanoma MO: State of the art and trends. Eur. J. Cancer 33:2302-2312; 1997.
33. Holder, W. D., Jr.; White, R. L., Jr.; Zuger, J. H.; Easton, E. J., Jr.; Greene, F. L. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann. Surg. 227:764-771; 1998.
34. Cochran, A. J.; Wen, D. R. S-100 protein as a marker for melanocytic and other tumours. Pathology 17:340-345; 1985.
35. Cormier, J. N.; Abati, A.; Fetsch, P.; Hijazi, Y. M.; Rosenberg, S. A.; Marincola, F. M.; Topalian, S. L. Comparative analysis of the in vivo expression of tyrosinasc, MART-1/Melan-A, and GP100 in metastatic melanoma lesions-implications for immunotherapy. J. Immunother. 21:27-31; 1998.
36. Kageshita, T.; Kawakami, Y.; Hirai, S.; Ono, T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J. Immunother. 20:460-465; 1997.
37. Chen, Y. T.; Stocken, E.; Tsang, S.; Coplan, K. A.; Old, L. J. Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development. Proc. Natl. Acad. Sci. USA 92:8125-8129; 1995.
38. Griffitt, W.; Click, R. P.; Lichtor, T.; Cohen, E. P. Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system. Neurosurgery 42:335-340; 1998.
39. Vlock, D. R.; Aul, D. J.; Toporowicz, A.; McCoy, J. P.; Brown, W. E. Purification and partial characterization of a shed 66 kDa melanoma-associated antigen identified by autologous antibody. Biochim. Biophys. Acta 1080:1-10; 1991.
40. Vedralova, E.; Borovansky, J. Evaluation of serum sialic acid fractions as markers for malignant melanoma. Cancer Lett. 78: 171-175; 1994.
41. Sidransky, D. Nucleic acid-based methods for the detection of cancer. Science 278:1054-1059; 1997.
42. Bosserhoff, A. K.; Hein, R.; Bogdahn, U.; Buettner, R. Structure and promoter analysis of the gene encoding the human melanomainhibiting protein MIA. J. Biol. Chem. 271:490-495; 1996.
43. La Valle, G. J.; Williams, N. Y.; Walker, M. J.; Triozzi, P. L.; Barbera-Guillem, E. Expression of melanoma inhibitory activity in the peripheral blood of melanoma patients by the reverse transcriptase-polymerase chain reaction (RT-PCR). Proc. Am. Assoc. Cancer Res. 39:229; 1998.
44. Gupta, R. K.; Lallu, S. Cytodiagnosis of amelanotic metastatic malignant melanoma: An immunocytochemical study. Diagn. Cylopathol. 16:238-241; 1997.